Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, today announced John A. Fallon, M.D. has joined its Board of Directors.
BOSTON--(BUSINESS WIRE)-- Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, today announced John A. Fallon, M.D. has joined its Board of Directors.
Dr. Fallon practiced internal medicine for more than 20 years and served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts (“BCBS MA”) from 2004 through 2015. Prior to his role at BCBS MA, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts.
“As Renovia prepares for commercial launch of our next-generation digital therapeutics, Dr. Fallon provides an ideal mix of clinical, payor, provider and corporate governance experience,” said Marc Beer, Co-Founder, Chairman and Chief Executive Officer of Renovia. “John’s guidance will be critical as we pursue new clinical studies, partnership opportunities and continue to leverage our technology platform to drive a new standard of care in women’s health.”
“Renovia’s investments in technology and clinical development are creating a compelling platform of digital therapeutics and diagnostics. This platform has the potential to not only improve individual patient outcomes but to do so through cost-effective, first-line treatments that aren’t available today,” said Dr. Fallon. “I am truly excited to work with the Renovia team as they prepare for commercial launch and even more so to help them apply population-level data for better diagnosis and treatment that could lead to individual and system-level savings.”
Dr. Fallon holds a B.A. from the College of the Holy Cross, an MBA from the University of South Florida and a Doctor of Medicine from Tufts University School of Medicine. Dr. Fallon, completed his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians.
Dr. Fallon serves on the Boards of Directors of Insulet Corporation, a medical devices company (Nasdaq:PODD); AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company (Nasdaq:AMAG); Exact Sciences Corporation, a molecular diagnostics company (Nasdaq:EXAS); and Collegium Pharmaceuticals, Inc., a specialty pharmaceutical company (Nasdaq:COLL); as well as the Board of the Network for Excellence in Health Innovation (NEHI) (Chair), a not-for-profit institution. Dr. Fallon previously served as Chairman of the Medical Standards Committee of the National Committee for Quality Assurance (NCQA) and on the Board of Directors of the New England Comparative Effectiveness Public Advisory Council (CEPAC).
About Renovia
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia’s technology enables treatment via precise visualization of pelvic movement in real time during pelvic floor muscle training, while monitoring usage and progress over time. As a women’s health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health. For more information, please visit here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005193/en/
Contacts
Jim Barron/Chris Kittredge/Tori Goodell
Sard Verbinnen & Co.
(212) 687-8080
Source: Renovia Inc.